Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526494-42-00

Enrollment

Registered

2026-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Brief summary

The primary variable of this study is to demonstrate the detection rates of the primary tumor, metastatic lymph nodes and distant metastases in gastric cancer with 18F-FAPI-74 PET/CT

Detailed description

Secondary variable is to demonstrate the detection of distant metastases with 18F-FAPI-74 PET/CT. PET findings are compared to the gold standard of histopathological findings, or in recurrent disease to histopathological findings or routine clinical follow-up CT in one year.

Interventions

DRUG[18F]FAPI-74

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary variable of this study is to demonstrate the detection rates of the primary tumor, metastatic lymph nodes and distant metastases in gastric cancer with 18F-FAPI-74 PET/CT	—

Secondary

Measure	Time frame
Secondary variable is to demonstrate the detection of distant metastases with 18F-FAPI-74 PET/CT. PET findings are compared to the gold standard of histopathological findings, or in recurrent disease to histopathological findings or routine clinical follow-up CT in one year.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 6, 2026